244 related articles for article (PubMed ID: 20614689)
1. Pharmacokinetic/pharmacodynamic model-based combination therapy approach to target antibiotic resistant populations emerged from ciprofloxacin exposure.
Wu B; Derendorf H
Pharmazie; 2010 Jun; 65(6):417-20. PubMed ID: 20614689
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa.
Maciá MD; Borrell N; Segura M; Gómez C; Pérez JL; Oliver A
Antimicrob Agents Chemother; 2006 Mar; 50(3):975-83. PubMed ID: 16495260
[TBL] [Abstract][Full Text] [Related]
3. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration.
Olofsson SK; Marcusson LL; Komp Lindgren P; Hughes D; Cars O
J Antimicrob Chemother; 2006 Jun; 57(6):1116-21. PubMed ID: 16624874
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of a once-daily treatment using ciprofloxacin in an extended-release dosage form.
Schuck EL; Dalhoff A; Stass H; Derendorf H
Infection; 2005 Dec; 33 Suppl 2():22-8. PubMed ID: 16518708
[TBL] [Abstract][Full Text] [Related]
5. Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
Plasencia V; Borrell N; Maciá MD; Moya B; Pérez JL; Oliver A
Antimicrob Agents Chemother; 2007 Jul; 51(7):2574-81. PubMed ID: 17470655
[TBL] [Abstract][Full Text] [Related]
6. Predicting mutant selection in competition experiments with ciprofloxacin-exposed Escherichia coli.
Khan DD; Lagerbäck P; Malmberg C; Kristoffersson AN; Wistrand-Yuen E; Sha C; Cars O; Andersson DI; Hughes D; Nielsen EI; Friberg LE
Int J Antimicrob Agents; 2018 Mar; 51(3):399-406. PubMed ID: 29127049
[TBL] [Abstract][Full Text] [Related]
7. Suppression of ciprofloxacin-induced resistant Pseudomonas aeruginosa in a dynamic kill curve system.
Wu BM; Sabarinath SN; Rand K; Johnson J; Derendorf H
Int J Antimicrob Agents; 2011 Jun; 37(6):519-24. PubMed ID: 21497064
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance.
Gumbo T; Louie A; Deziel MR; Drusano GL
Antimicrob Agents Chemother; 2005 Aug; 49(8):3178-81. PubMed ID: 16048921
[TBL] [Abstract][Full Text] [Related]
9. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
Louie A; Brown DL; Liu W; Kulawy RW; Deziel MR; Drusano GL
Antimicrob Agents Chemother; 2007 Nov; 51(11):3988-4000. PubMed ID: 17846144
[TBL] [Abstract][Full Text] [Related]
10. A mechanism-based pharmacokinetic/pharmacodynamic model allows prediction of antibiotic killing from MIC values for WT and mutants.
Khan DD; Lagerbäck P; Cao S; Lustig U; Nielsen EI; Cars O; Hughes D; Andersson DI; Friberg LE
J Antimicrob Chemother; 2015 Nov; 70(11):3051-60. PubMed ID: 26349518
[TBL] [Abstract][Full Text] [Related]
11. Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments.
Nielsen EI; Viberg A; Löwdin E; Cars O; Karlsson MO; Sandström M
Antimicrob Agents Chemother; 2007 Jan; 51(1):128-36. PubMed ID: 17060524
[TBL] [Abstract][Full Text] [Related]
12. Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion.
Firsov AA; Smirnova MV; Strukova EN; Vostrov SN; Portnoy YA; Zinner SH
Int J Antimicrob Agents; 2008 Dec; 32(6):488-93. PubMed ID: 18790614
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics: relation to antimicrobial resistance.
Rybak MJ
Am J Infect Control; 2006 Jun; 34(5 Suppl 1):S38-45; discussion S64-73. PubMed ID: 16813981
[TBL] [Abstract][Full Text] [Related]
14. Effect of GrlA mutation on the development of quinolone resistance in Staphylococcus aureus in an in vitro pharmacokinetic model.
Oonishi Y; Mitsuyama J; Yamaguchi K
J Antimicrob Chemother; 2007 Nov; 60(5):1030-7. PubMed ID: 17827137
[TBL] [Abstract][Full Text] [Related]
15. Effects of antimicrobials on the competitive growth of Streptococcus pneumoniae: a pharmacodynamic in vitro model approach to selection of resistant populations.
Sevillano D; Aguilar L; Alou L; Giménez MJ; Echevarría O; Cafini F; Valero E; Fenoll A; Prieto J
J Antimicrob Chemother; 2006 Oct; 58(4):794-801. PubMed ID: 16880173
[TBL] [Abstract][Full Text] [Related]
16. Ciprofloxacin use in critically ill patients: pharmacokinetic and pharmacodynamic approaches.
Conil JM; Georges B; de Lussy A; Khachman D; Seguin T; Ruiz S; Cougot P; Fourcade O; Houin G; Saivin S
Int J Antimicrob Agents; 2008 Dec; 32(6):505-10. PubMed ID: 18768301
[TBL] [Abstract][Full Text] [Related]
17. Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa.
Pasquali F; Manfreda G
Vet Microbiol; 2007 Jan; 119(2-4):304-10. PubMed ID: 16987619
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of action of and resistance to ciprofloxacin.
Hooper DC; Wolfson JS; Ng EY; Swartz MN
Am J Med; 1987 Apr; 82(4A):12-20. PubMed ID: 3034057
[TBL] [Abstract][Full Text] [Related]
19. Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data.
Burgess DS; Hall RG
Clin Ther; 2007 Jul; 29(7):1421-7. PubMed ID: 17825693
[TBL] [Abstract][Full Text] [Related]
20. The PK/PD index (CMAX/MIC) for ciprofloxacin in patients with cystic fibrosis.
Szałek E; Kamińska A; Gozdzik-Spychalska J; Grześkowiak E; Batura-Gabryel H
Acta Pol Pharm; 2011; 68(5):777-83. PubMed ID: 21928725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
